Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
Boehringer Ingelheim
Hoffmann-La Roche
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Hoffmann-La Roche
BioNTech SE
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Intergroupe Francophone de Cancerologie Thoracique
InSightec
Hoffmann-La Roche
Intergroupe Francophone de Cancerologie Thoracique
Shanghai Henlius Biotech
ImmunityBio, Inc.
Hoffmann-La Roche
Gruppo Oncologico Italiano di Ricerca Clinica
Peking University Cancer Hospital & Institute
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Samsung Medical Center
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche